Voyager Therapeutics Reports Second Quarter 2023 Financial and Operating Results

– Introduced new vectorized anti-Aβ antibody gene therapy research initiative, expanding Alzheimer’s disease portfolio – – Executed license agreement with Sangamo for prion disease treatment – – Presented validating preclinical results including increased brain transduction of IV-administered